Satellos' new Duchenne study endpoint; Amgen's Repatha cuts heart attack risk

EndpointsView source article

Part of story

Amgen's Repatha linked to fewer heart attacks versus Zetia in new data

New data from Amgen showed its PCSK9 inhibitor Repatha reduced heart attack risk by approximately 20% more than Zetia (ezetimibe) in patients where statins are insufficient.

Nov 5, 20262 sourcesClinical trials Cardiovascular diseases Gene therapy Pharmaceutical Industry Drug safety & pharmacovigilance Cholesterol management

Amgen's Repatha linked to fewer heart attacks versus Zetia in new data

Other sources for this story

STAT News